Pfizer (PFE) Stock Rises as Monthly Weight-Loss Drug Data Impresses

TLDR

• Pfizer unveiled Phase 2b data for berobenatide, a once-monthly GLP-1 injection showing ~15% body weight loss in trials
• The drug could be the first monthly obesity therapy in its class, competing against weekly options like Wegovy and Zepbound
• Pfizer plans 20+ trials in obesity and metabolic conditions in 2026, including 10 Phase 3 studies for berobenatide
• A $10.5 billion partnership with Innovent Biologics covers 12 cancer drugs, with only $650 million owed upfront
• Patent losses on Eliquis, Ibrance, and Xtandi — worth over $20 billion in 2025 revenue — loom large for the dividend

---

Pfizer (PFE) stock edged up 1.36% to $26.04 as the company laid out an ambitious push into obesity, cancer, and vaccines, but its long-term story still hinges on managing a looming patent cliff.

Pfizer Inc., PFE

The biggest headline came from the American Diabetes Association conference in New Orleans, where Pfizer presented new data on berobenatide, its long-acting GLP-1 receptor agonist acquired through last year’s $10 billion Metsera deal.

In the Phase 2b VESPER-1 study, patients on the highest weekly dose lost 15.9% of body weight over eight months with no sign of a plateau. A separate trial, VESPER-3, showed patients on a once-monthly dose lost nearly 15% of body weight over 14 months.

That monthly dosing schedule is the key selling point. Pfizer is positioning berobenatide as potentially the first once-a-month GLP-1 therapy, going up against Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, both of which require weekly injections.

“Weight management is a lifelong commitment, and the barriers to staying on therapy long-term are just as important as the therapy itself,” said John B. Buse of the University of North Carolina School of Medicine.

Pfizer’s chief internal medicine officer Jim List added that the drug “delivered continuous, uninterrupted weight loss at all doses” in Phase 2b, while remaining tolerable as patients shifted from weekly to monthly dosing.

The company plans to run more than 20 trials across obesity and related conditions this year, including 10 active and planned Phase 3 studies for berobenatide. Expansion into China and Japan is also planned.

Cancer and Vaccines Fill Out the Pipeline

Pfizer is also moving on two other fronts. In oncology, it has launched several Phase 1b/2 and Phase 2 trials combining its experimental antibody-based drug PF-08634404 with other agents in bladder cancer, transformed small cell lung cancer, and advanced solid tumors, partly in partnership with Astellas.

On the vaccine side, Pfizer has started recruiting for a Phase 3 trial of PG4, a next-generation pneumococcal conjugate vaccine for infants designed to compete with or replace its own Prevnar 20.

The Innovent Biologics deal covers 12 cancer drugs across both companies’ pipelines. Pfizer owes only $650 million upfront, with the remaining $9.85 billion tied to developmental, regulatory, and commercial milestones.

Dividend Risk Remains Real

Despite the pipeline activity, Pfizer faces a difficult financial picture. Revenue last year was $62.6 billion, down sharply from the $100 billion peak in 2022. Three of its top drugs — Eliquis, Ibrance, and Xtandi — face patent expiry next year, representing more than $20 billion in 2025 revenue.

Long-term debt stands at $60.5 billion, costing $670 million in interest per quarter. CEO Albert Bourla has flagged a “five-year period of high-single-digit revenue CAGR” starting in 2029, following recent patent settlements on Vyndamax.

The forward dividend yield sits at 6.7%, reflecting both the income on offer and the risk attached to it.